Equity Profile

NKTR

Nektar Therapeutics

Health CarePharmaceuticals$2.6B

Nov8Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EST

Company Snapshot

Nektar Therapeutics is a pharmaceutical company focused on developing innovative therapies for patients with serious diseases. With a market cap of $3 billion, it operates in the health care sector, which is seeing increasing demand for new treatments and therapies, particularly in oncology and autoimmune diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NKTR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

In the last quarter, Nektar reported an EPS of -$1.82, slightly missing analyst expectations. The stock reacted negatively, dropping 2.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for this quarter are mixed, with no analyst estimates available. The market is likely looking for signs of recovery in earnings and revenue.

Bull Case

If Nektar can demonstrate significant progress in its clinical trials and show improved revenue, it could lead to a positive market reaction and a potential rally in the stock price.

Bear Case

Conversely, if the company continues to report larger-than-expected losses or fails to provide updates on its pipeline, investor confidence may wane, leading to further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Nektar's clinical trials and any expected timelines for results?

The outcome of these trials could significantly influence future revenue potential and investor sentiment.

How does management plan to address the recent trend of increasing EPS losses?

Investors will be looking for a clear strategy to improve financial performance and restore confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nektar's clinical trials to yield positive results, which could dramatically shift investor sentiment.

Supporting Evidence

Options are pricing a significant move, indicating that traders expect volatility, which could reflect underlying positive developments.

The company's previous EPS surprises show that it can outperform expectations, suggesting potential upside.

Key Risk

If clinical trial results show significant promise, it could lead to a re-evaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Nektar's ability to stabilize its financial performance while progressing in its clinical trials.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate improved operational efficiency and investor confidence.

Bear Confirmed If

If EPS losses exceed -$2.00, it would confirm ongoing financial struggles and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±11.48%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move of about 11.5%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.5% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

62.9%

Calls (67K)P/C Ratio: 1.63Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations, history suggests a potential stock increase of around 1.58% on the following day, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may see a muted reaction, reflecting ongoing caution among investors.

Miss

Should the company miss expectations again, history suggests a potential decline of about 0.10%, indicating continued investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines and results of ongoing clinical trials.
2Management's strategy for reducing EPS losses and improving financial health.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market demand for Nektar's therapies and how they plan to capitalize on it.
5Comments on competitive landscape and how Nektar differentiates itself.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

EOG Resources, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and commercialize its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NKTR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

In the last quarter, Nektar reported an EPS of -$1.82, slightly missing analyst expectations. The stock reacted negatively, dropping 2.02% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for this quarter are mixed, with no analyst estimates available. The market is likely looking for signs of recovery in earnings and revenue.

Bull Case

If Nektar can demonstrate significant progress in its clinical trials and show improved revenue, it could lead to a positive market reaction and a potential rally in the stock price.

Bear Case

Conversely, if the company continues to report larger-than-expected losses or fails to provide updates on its pipeline, investor confidence may wane, leading to further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Nektar's clinical trials and any expected timelines for results?

The outcome of these trials could significantly influence future revenue potential and investor sentiment.

How does management plan to address the recent trend of increasing EPS losses?

Investors will be looking for a clear strategy to improve financial performance and restore confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nektar's clinical trials to yield positive results, which could dramatically shift investor sentiment.

Supporting Evidence

Options are pricing a significant move, indicating that traders expect volatility, which could reflect underlying positive developments.

The company's previous EPS surprises show that it can outperform expectations, suggesting potential upside.

Key Risk

If clinical trial results show significant promise, it could lead to a re-evaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Nektar's ability to stabilize its financial performance while progressing in its clinical trials.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate improved operational efficiency and investor confidence.

Bear Confirmed If

If EPS losses exceed -$2.00, it would confirm ongoing financial struggles and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±11.48%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move of about 11.5%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.5% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

62.9%

Calls (67K)P/C Ratio: 1.63Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations, history suggests a potential stock increase of around 1.58% on the following day, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may see a muted reaction, reflecting ongoing caution among investors.

Miss

Should the company miss expectations again, history suggests a potential decline of about 0.10%, indicating continued investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines and results of ongoing clinical trials.
2Management's strategy for reducing EPS losses and improving financial health.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market demand for Nektar's therapies and how they plan to capitalize on it.
5Comments on competitive landscape and how Nektar differentiates itself.